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Prognosis and survival for malignant melanoma is highly dependent on early diagnosis 
and treatment. While the American Joint Committee on Cancer (AJCC) criterion provides 
a means of staging melanomas and guiding treatment approaches, it is unable to identify 
the risk of disease progression of early stage tumors or provide reliable stratification for 
novel adjuvant therapies. The demand for credible prognostic/companion biomarkers 
able to identify high-risk melanoma subgroups as well as guide more effective person-
alized/precision-based therapy is therefore of paramount importance. Autophagy, the 
principle lysosomal-mediated process for the degradation/recycling of cellular debris, 
is a hot topic in cancer medicine, and observations of its deregulation in melanoma 
have brought its potential as a prognostic biomarker to the forefront of current research. 
Key regulatory proteins, including Atg8/microtubule-associated light chain 3 (LC3) and 
BECN1 (Beclin 1), have been proposed as potential prognostic biomarkers. However, 
given the dynamic nature of autophagy, their expression in vitro does not translate to 
their use as a prognostic biomarker for melanoma in vivo. We have recently identified the 
expression levels of Sequestosome1/SQSTM1 (p62) and activating molecule in Beclin 
1-regulated autophagy protein 1 (AMBRA1) as novel independent prognostic biomarkers 
for early stage melanomas. While increasing followed by subsequent decreasing levels of 
p62 expression reflects the paradoxical role of autophagy in melanoma, expression levels 
additionally define a novel prognostic biomarker for AJCC stage II tumors. Conversely, 
loss of AMBRA1 in the epidermis overlying primary melanomas defines a novel prog-
nostic biomarker for AJCC stage I tumors. Collectively, the definition of AMBRA1 and 
p62 as prognostic biomarkers for early stage melanomas provides novel and accurate 
means through which to identify tumors at risk of disease progression, facilitating earlier 
patient therapeutic intervention and stratification tools for novel personalized therapeutic 
approaches to improve clinical outcome.
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Malignant melanoma, the most aggressive form of skin cancer arising from the malignant trans-
formation of melanocytes, is an increasing public health concern worldwide with incidence rates 
doubling every 10–20 years (1), which now renders this malignancy accountable for 75% of all skin 
cancer deaths and the most common cause of cancer-related mortality in young individuals between 
20 and 35 years of age (2).
As with many cancers, prognosis and survival for melanoma is highly dependent on early detec-
tion, diagnosis, and treatment. In line with this need and coupled with the emergence of novel 
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targeted and immunotherapies, current interest is focused on the 
discovery of predictive and prognostic biomarkers. A biomarker 
refers to any measurable diagnostic indicator that is used to assess 
the risk or presence of disease (3). While predictive biomarkers are 
able to indicate which patient subgroups are likely to benefit from 
certain treatments (4), prognostic markers enable stratification of 
patients at initial diagnosis according to eventual outcome, which 
can be used clinically to guide patient management including the 
earlier initiation of adjuvant therapies in patients at high risk of 
disease progression, potentially preventing the development of 
untreatable metastatic disease (5).
Some of the best established prognostic biomarkers for 
melanoma are incorporated into the current American Joint 
Committee on Cancer (AJCC) 2009 staging criterion, the most 
comprehensive staging system for melanoma to date, which 
remains the international standard for disease staging and 
as a guide for treatment approaches. AJCC staging combines 
several prognostic factors for melanoma, including the depth 
of invasion (Breslow depth), rate of mitoses, presence of ulcera-
tion (loss of the epidermis overlying the tumor), evidence of 
metastatic spread, and changes in serum lactate dehydrogenase 
(LDH) to allow risk stratification of morbidity and mortality at 
the initial diagnosis (6). In general, this divides malignant mela-
noma into four stages: stages I–II comprising primary tumors 
of distinct thickness (defined as early stage disease), stage III 
where locoregional spread of disease (mainly to local lymph 
node basins) is present, and stage IV where there is presence of 
distant metastasis.
While early stage melanoma is largely curative by surgi-
cal excision, metastatic disease represents the cause of death 
from melanoma in the vast majority of cases due to a lack of 
consistently beneficial treatment regimens for late stage disease. 
Furthermore, despite its comprehensiveness, AJCC staging as a 
prognostic biomarker is limited by the inability of its criteria to 
accurately identify high-risk melanoma subgroups that will go on 
to progress; a particular problem in seemingly “low risk” AJCC 
stage I melanomas where up to 10% of tumors subsequently 
metastasize. This emphasizes the urgent need for novel credible 
biomarkers to identify high-risk tumors as well as the stratifica-
tion of such patients for more efficacious and earlier therapeutic 
approaches (6).
Observations of deregulated autophagy in many cancers, 
including melanoma, have brought this key signaling mechanism 
to the forefront of much research (7, 8), including its potential 
capacity as a prognostic biomarker. Autophagy, the principle cata-
bolic process for lysosomal-mediated degradation of intracellular 
components to sustain cellular energy and survival, is regulated 
by a complex signaling cascade involving ubiquitin-like conjuga-
tion systems, autophagy regulatory proteins [BECN1/Beclin 1 
(Beclin-1), activating molecule in Beclin 1-regulated autophagy 
protein 1 (AMBRA1), Atg8/microtubule-associated light chain 3 
LC3 (LC3), and Sequestosome1/SQSTM1 (p62)], and the inac-
tivation of mammalian target of rapamycin (mTOR) to induce 
activation. Cellular debris within the cytoplasm is sequestered 
into double-membrane autophagosomes, which are then deliv-
ered to lysosomes for degradation and recycling (9). In cancer, 
however, autophagy plays a paradoxical role; on the one hand, 
preventing build-up of toxic cellular components that result in 
genomic stress and instability, thereby promoting tumorigenesis, 
while, on the other hand, promoting tumor survival of advanced 
stage solid tumors such as melanoma in a nutrient-deprived 
hypoxic environment (10). Consistent with the paradoxical role 
of autophagy and in contrast to observations in benign nevi, elec-
tron microscopy studies have shown an increased presence and 
vacuolization (suggesting degradation) of double-membraned 
autophagosomes in the cytoplasm of metastatic melanoma cells, 
thus supporting the notion of increased autophagic activity in 
advanced stage disease (11, 12).
BRAF is a member of the RAF group of serine/threonine 
protein kinases, and as such functions to regulate the mitogen-
activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) cellular growth pathway (13). Activating mutations 
in BRAF, present and in up to 70% of all melanomas along 
with NRas mutations (present in approximately 15–20% of 
melanomas), result in constitutive activation of MAPK signal-
ing, promoting growth, survival, and chemoresistance (14–17). 
Interestingly, BRAF mutational status in melanoma has also been 
shown to variably influence autophagy. Following treatment of 
BRAF wild-type melanoma cells with endoplasmic reticulum 
(ER) stress-inducing agents in  vitro, autophagy is activated 
in line with its pro-survival role; however, when autophagy is 
inhibited exogenously, this leads to increased cell death (12, 18). 
Conversely, oncogenic BRAF induces a chronic ER stress status, 
resulting in enhanced basal autophagy [as evidenced by increased 
Atg8-PE/LC3-II (LC3-II) expression], resistance of melanoma 
cells to apoptosis, and insensitivity to further autophagy induc-
tion. This suggests that although melanomas rely on increased 
innate autophagic activity, BRAF-mutated tumors are resistant 
to further mTOR-dependant stimulation of autophagy and that 
while combined inhibition of autophagy with chemotherapy 
might be a viable therapeutic avenue for BRAF wild-type mela-
nomas, targeted therapies that attenuate ER stress may prove a 
more effective treatment strategy for BRAF mutant melanomas 
(12, 18, 19).
To date, several markers of autophagy, including LC3 and 
Beclin 1, have been identified as potential prognostic biomarkers 
for melanoma. Under normal homeostatic conditions, exogenous 
LC3 is cytoplasmic but upon autophagy induction becomes con-
jugated to phosphatidylethanolamine (PE) to form the membrane 
bound form LC3-II, thus acting as a marker of autophagy induc-
tion (20). Increased immunohistochemical expression of LC3 
has been shown in malignant melanomas compared to benign 
nevi (21) and is associated with the development of metastatic 
disease and poorer outcomes (22). In addition, studies of Beclin 
1 expression suggest its’ downregulation parallels melanoma 
disease stage progression, further supporting a role for autophagy 
in tumor invasion and metastasis (23, 24). However, although the 
expression of LC3 provides an indication of autophagy status in 
melanoma, it is important to note that conversion of LC3-I to 
LC3-II is a dynamic process, thus limiting the capacity of endog-
enous LC3 expression as an accurate biomarker of autophagy 
status and importantly, the reflection of autophagic flux (15). 
Moreover, although reported to be downregulated in melanoma, 
there is also conflicting evidence of Beclin 1 overexpression in 
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advanced melanoma, thus questioning its expression as a reliable 
prognostic biomarker (25).
Sequestosome1/SQSTM1 is a scaffold protein that shuttles 
ubiquitinated proteins into the autophagosome, later degraded 
along with other autophagosomal contents upon fusion with 
a lysosome. Impairment of autophagy is therefore reflected by 
an associated accumulation of p62, a process reported to be a 
key to the onset of tumorigenesis (17). Conversely, decreased 
levels of p62 reflect active autophagy, as observed in advanced 
stage melanomas where autophagy is commonly reactivated to 
enhance tumor survival (Figure  1A). Data from our lab have 
further defined p62 expression as a prognostic biomarker for 
melanoma where a stepwise increase in expression is observed 
in early AJCC stage melanomas (increased above basal levels in 
benign nevi and reflecting deregulated autophagy) but which is 
subsequently decreased in advanced metastatic tumors, consist-
ent with the reactivation of autophagy and its paradoxical role 
in cancer [Figures 1B,C; (26)]. Furthermore, univariate analysis 
showed a significantly increased risk of metastasis in AJCC stage 
II tumors with low p62 expression (<20% median p62 expression) 
compared to those with high expression (>20% p62 expression) 
[Figure 1D; (26)]. Moreover, since there was no association with 
FiGURe 1 | p62 expression is a prognostic biomarker for AJCC stage ii melanomas. (A) Schematic of the paradoxical role of autophagy in melanoma in the 
context of p62 expression; impairment of autophagy drives tumorigenesis of early stage melanomas reflected by p62 accumulation, whereas decreased levels of 
p62 seen in advanced disease reflect autophagy reactivation. (B) Mean % p62 expression in a cohort of eventual AJCC stage I, II, III, and IV melanomas or benign 
nevi after a minimum 5-year follow-up. Each point represents the mean % of p62 positive cells. Horizontal lines representing median p62 expression levels indicate 
an increase in median p62 expression levels between benign nevi and AJCC stage I or II melanomas and a relative decrease in expression in advanced AJCC 
stages III and IV tumors (Kruskal–Wallis P < 0.0001) (26). (C) Photomicrographs of immunohistochemical p62 expression and mean % in a melanocytic nevus or an 
eventual AJCC stage I, II, or IV melanoma. Scale bar = 100 μm. (D) Univariate analysis of mean p62 expression in AJCC stage II primary tumors demonstrating an 
increased risk of metastasis in tumors expressing >20% p62 [Log-Rank (Mantel–Cox) P = 0.031, HR 2.29 (95% CI 1.08–4.86)], and highlighting the potential of p62 
as a prognostic biomarker (26).
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Breslow depth or tumor ulceration, p62 expression defines an 
independent stratifying variable from AJCC staging prognostica-
tors. Collectively, these data highlight p62 as a novel independent 
prognostic biomarker for AJCC stage II melanomas, providing 
a powerful tool for refining the risk of disease progression and 
enabling earlier patient therapeutic intervention. In addition, p62 
expression may represent a companion biomarker of response to 
autophagy modulation in vivo, an important concept in view of 
emerging autophagy modulator therapies (27) and their potential 
to improve overall clinical outcome for patients with metastatic 
melanoma.
Activating molecule in Beclin 1-regulated protein 1 (AMBRA1) 
is a component of the Beclin 1/VPS34 complex and involved in 
the formation of PI3K rich membranes during the nucleation 
phase of autophagy [Figure 2A; (28)]. As a key autophagy initiat-
ing regulatory protein, AMBRA1 represents a potential marker 
of autophagy induction as well as a possible therapeutic target 
for autophagy inhibition. However, in addition to its functional 
role in autophagy, a growing body of evidence supports a role 
for AMBRA1 in cellular differentiation (29, 30) including in the 
early differentiation of neuronal stem cells in which autophagy is 
activated to fulfill the high energy demands of this process (28, 
31). In line with these findings, we have recently demonstrated 
the role of AMBRA1 in epidermal differentiation with the expres-
sion in vivo increasing in line with keratinocyte differentiation 
from the basal layer of the epidermis to the uppermost layer, the 
stratum corneum (32). Unlike p62, however, the expression of 
AMBRA1 in primary melanomas is variable and as such its value 
as a tumoral biomarker remains undefined. Strikingly, however, 
our recent data demonstrate the decreased or even complete loss 
of AMBRA1 expression in the epidermis overlying many AJCC 
stage I melanomas (Figure 2B), which did not correlate with the 
degree of epidermal invasion and was not observed in benign 
nevi (32). These data suggest that the expression of AMBRA1 in 
the melanoma microenvironment may have prognostic potential. 
Univariate analysis of an initial cohort of 129 all AJCC stage 
melanomas further revealed decreased or loss of epidermal 
AMBRA1 expression was significantly associated with decreased 
disease-free survival, with stratification for AJCC stage I disease, 
additionally revealing epidermal AMBRA1 expression as a puta-
tive biomarker of disease progression [Figure 2C; (32)]. Again, 
there was no correlation with Breslow depth suggesting, such as 
FiGURe 2 | Loss of epidermal AMBRA1 identifies a high-risk AJCC stage i melanoma subgroup. (A) Schematic representation of the autophagy pathway 
highlighting the role of AMBRA1 in the nucleation phase of autophagy and indicating interplay of p62. (B) Representative immunohistochemistry images of epidermal 
AMBRA1 expression depicting maintained (top image) or loss of AMBRA1 expression (bottom image) in the epidermis overlying AJCC stage I melanomas. Loss of 
epidermal AMBRA1 expression overlying the tumor tissue creates a “watershed” area, where the epidermis distant to the tumor reveals a normal pattern of 
AMBRA1 expression. Scale bar = 100 μm. (C) Kaplan–Meier curve showing decreased 7-year disease-free survival in 51 AJCC stage I tumors where epidermal 
AMBRA1 was decreased or lost as compared with 22 tumors where AMBRA1 expression was maintained [Log-Rank (Mantel–Cox) test P < 0.03, HR 4.3 (95% CI 
1.14–16.51)]. Epidermal AMBRA1 expression of each tumor was recorded as being either maintained, decreased, or lost based on the perceived degree of loss of 
epidermal AMBRA 1 expression overlying the tumor bulk compared to normal epidermis within the same section.
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p62, that epidermal AMBRA1 expression is also a biologically 
distinct marker for AJCC stage I melanomas. This is a striking 
finding considering that these tumors are normally regarded 
as low risk, with currently no alternative means of identifying 
specific individuals whose tumors are likely to progress.
Since the current and universally adopted AJCC staging 
system is unable to identify the risk of disease progression in 
seemingly “low risk” early stage melanomas, such tumors are 
only identified after the onset of metastatic disease progression, 
at which point treatment options are limited and frequently inef-
fective. Critically, identifying, refining, and validating prognostic 
biomarkers for early stage melanomas such as the proposed 
biomarkers of autophagy will thus enable the identification of 
high-risk tumor subgroups. Both p62 and AMBRA1 expres-
sion exemplify how autophagy can be harnessed as prognostic 
biomarkers for melanoma, each providing clinically relevant 
information over and above AJCC staging, which in particular 
will be useful for refining the risk of melanoma progression in 
patients with AJCC stage I or II melanomas. Ultimately, further 
validation of these biomarkers will allow application in a clinical 
context, facilitating both earlier therapeutic intervention and the 
refinement of personalized therapies for malignant melanoma to 
improve clinical outcome and the prevention of premature loss 
of life.
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